Background and Aims: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise in metabolic dysfunction-associated steatotic liver disease (MASLD). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.